Clinical-stage cell therapy company Shanghai Grit Biotechnology ... on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours. Quanqi (125SER) is a marketed ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Conclusions Treg defects in patients with SLE are associated with IL-2 deficiency, and can be corrected with low doses of IL-2. The restoration of endogenous mechanisms of immune tolerance by low-dose ...

MedStar Georgetown University Hospital is the first hospital in the Washington metropolitan area to offer Tumor-Infiltrating ...

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Background—In the lipopolysaccharide (LPS) stimulated peripheral blood monocyte, the precursor form of interleukin 1β (IL-1β, 31 kD ... significantly reduced the amount of mature IL-1β released by ...

Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy ... Assessment of Psoriasis and Psoriatic Arthritis guidelines advise methotrexate ...

at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will ...

Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...